Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

The PARP Combo Race Is On: Clovis And Bristol Partner On Rubraca

Executive Summary

Amidst excitement over the potential of PD-1/PARP inhibitor combos in multiple tumor types, Clovis signs a non-exclusive agreement to test Rubraca with Bristol's Opdivo in ovarian, breast and prostate cancer.

Advertisement

Related Content

Ovarian Cancer Pipeline Review: Sponsors Plan Frontline Punch, Smart Combinations
How Ovarian Cancer Maintenance Therapies Stack Up On Costs And Value
Think Positive: Clovis Confident Of CHMP Okay For Rubraca
Lynparza Partners AZ And Merck & Co Target US Breast Cancer Market
Lynparza Poised For Growth With Broad Ovarian Cancer Approval
A Whopper Of A Deal: AZ Hands Half Of Lynparza To Merck
MYSTIC Misses: Devastation For AstraZeneca As Imfinzi Fails PFS Endpoint In NSCLC
Clovis's Rubraca Leapfrogs Rivals In Ovarian Cancer As ARIEL3 Hits
Tesaro's Zejula Expansion Includes Keytruda Combo, Lung Cancer
Clovis Transitions To Commercial Stage On Rubraca Approval

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

SC099237

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel